logo-loader
view712 North

712 North excited to be funded by the National Institute of Health

712 North CEO Marcel V. Alavi spoke with Proactive at the Bio Investor Forum in San Francisco. 
Privately-held 712 North is an early-stage biotech developing personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Opyl is new name of digital health track company ShareRoot

Opyl Limited (ASX:OPL) chief executive officer Michelle Gallaher updates Proactive on the renaming of the global digital health track company formerly known as ShareRoot Ltd (ASX:SRO). This heralds the company’s entry into the rapidly expanding global digital health and artificial...

5 hours, 58 minutes ago

2 min read